You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 144 No. 7, July 2008 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Dermatologic Disorders, Other
 •Phototherapy
 •Alert me on articles by topic

UV-A1 Phototherapy for Sclerotic Skin Diseases

Implications for Optimizing Patient Selection and Management

Alexander Kreuter, MD; Thilo Gambichler, MD

Arch Dermatol. 2008;144(7):912-916.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Phototherapy is among our most powerful weapons for fighting against chronic inflammatory skin diseases. Since the middle of the past century, numerous controlled studies of broadband UV-B, narrowband UV-B, and psoralen plus UV-A have demonstrated that phototherapy is highly effective in treating cutaneous diseases, such as psoriasis and atopic dermatitis. In 1981, the development of a new lamp that emits radiation predominantly between 340 and 400 nm was described, introducing the era of UV-A1 phototherapy.1 Three different dosage regimens of UV-A1 are distinguished: high-, medium-, and low-dose UV-A1, emitting 90 to 130, 30 to 89, and less than 30 J/cm2, respectively. In contrast to UV-B, which penetrates into the papillary dermis only, longer wavelengths in the UV-A region can reach the subcutis as well. In 1992, UV-A1 was first introduced as a highly potent treatment option for acute atopic dermatitis.2 Three years later, . . . [Full Text of this Article]

INDICATIONS FOR TREATMENT AND UV-A1 DOSAGE


MECHANISM OF ACTION AND TREATMENT SCHEDULE FOR UV-A1

EVALUATION OF TREATMENT RESPONSE

LIMITATIONS OF UV-A1 IN SCLEROTIC SKIN DISEASES

AUTHOR INFORMATION

RELATED ARTICLE

Effect of Increased Pigmentation on the Antifibrotic Response of Human Skin to UV-A1 Phototherapy
Frank Wang, Luis A. Garza, Soyun Cho, Reza Kafi, Craig Hammerberg, Taihao Quan, Ted Hamilton, Maureen Mayes, Voravit Ratanatharathorn, John J. Voorhees, Gary J. Fisher, and Sewon Kang
Arch Dermatol. 2008;144(7):851-858.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.